Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada.

ABSTRACT:

Introduction

Genetic testing in advanced prostate cancer is rapidly moving to become standard of care. Testing for genetic alterations in genes involved in DNA repair pathways, particularly those implicated in the homologous recombination repair (HRR) pathway, in patients with metastatic prostate cancer (mPCa) can inform selection of optimal therapies, as well as provide information about familial cancer risks; however, there are currently no consistent Canadian guidelines in place for genetic testing in mPCa.

Methods

A multidisciplinary steering committee guided the process of an environmental scan to define the current landscape, as well as the perceived challenges, through interviews with specialists from 14 sites across Canada. The challenges most commonly identified inc

SUBMITTER: Selvarajah S 

PROVIDER: S-EPMC9565071 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature